Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial

Table 2 Change in tumor expression from baseline (i.e. before atorvastatin treatment) to time of surgery (i.e. after atorvastatin treatment)

	Complete pairs	Decreasing	Unaltered	Increasing	P-value
ER	n = 30	2	25	3	0.68
PR	n = 30	3	21	6	0.19
HER2	n = 29	7	20	2	0.08
Cyclin D1 nuclear fraction	n = 30	4	19	7	0.12
Cyclin D1 nuclear intensity	n = 30	14	13	3	0.008*
Cyclin D1 cytoplasmic intensity	n = 30	10	14	6	0.48
p27 nuclear fraction	n = 33	2	22	9	0.03
p27 nuclear intensity	n = 33	9	18	6	0.35
p27 cytoplasmic intensity	n = 33	3	18	12	0.02

P-values from Wilcoxon matched-pairs signed-ranks test.
ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2.
*Significant even after Bonferroni adjustment for multiple testing within the marker, P = 0.02.

ISSN: 1479-5876